Cholesterol

A heightened ratio of non-high-density lipoprotein cholesterol (non-HDL-C) to HDL-C was associated with depression, with risk mediated by body mass index.

An index of total cholesterol, high-density lipoprotein (HDL), and fasting glucose levels was found to indicate the prevalence of type 2 diabetes in a nationally representative US cohort.

The ratio of high-density lipoprotein cholesterol (HDL-C) to low-density lipoprotein cholesterol (LDL-C) can predict cardiovascular disease (CVD) risk in patients with and without diabetes.

A retrospective analysis found no associations between lipid parameters and the success of blood stem cell mobilization in a cohort of healthy donors.

The angiopoietin-like-3-targeting treatment received an expanded indication for individuals aged 1 through 5 years, building on earlier approvals in older populations.

New research reveals that eggs do not raise bad cholesterol; instead, saturated fat in the diet is the real culprit for heart disease.

Inclisiran, a small interfering RNA PCSK9 inhibitor, was effective and tolerable in real-world practice, though pharmacists must make important considerations for patients switching from another medicine.

A meta-analysis found that proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors induce sustained reductions across lipid biomarkers, including low-density lipoprotein cholesterol (LDL-C).

Young, non-diabetic individuals were most likely to delay statin initiation for low-density lipoprotein cholesterol (LDL-C) lowering, increasing their risk of myocardial infarction.

Participating in a pharmacist-led secondary intervention clinic helped achieve large reductions in cholesterol levels among patients who have experienced an acute coronary syndrome.

A series of PCSK9 inhibitors were found to be tolerable and effective at reducing low-density lipoprotein cholesterol in solid organ transplant recipients.

Recaticimab significantly lowered low-density lipoprotein cholesterol (LDL-C) levels, showing promise in becoming a future proprotein convertase subtilisin/kexin type 9 (PCSK9) option for cholesterol reduction.

In combination with lipid-lowering therapy, inclisiran allowed patients with hypercholesterolemia to reach their low-density lipoprotein cholesterol (LDL-C) goals without associated muscle-related adverse events.

A new oral PCSK9 inhibitor, enlicitide, shows promise in significantly lowering LDL cholesterol, offering hope for hypercholesterolemia management and cardiovascular health.

A retrospective analysis found widespread lack of low-density lipoprotein cholesterol (LDL-C) goal attainment, posing risks for those at very high cardiovascular risk.

Self-medication, including the use of dietary supplements and pain relief drugs, were reported by many patients with statin-associated muscle symptoms to lower their low-density lipoprotein cholesterol (LDL-C).

A systematic review and meta-analysis revealed key insights into lipid parameters in patients with systemic sclerosis.

High-density lipoprotein cholesterol, known for protective cardiovascular effects, could play a role in reducing the risk of stress urinary incontinence.

By improving low-density lipoprotein cholesterol (LDL-C) levels, statins reduced complications after pipeline embolization device implantation for intracranial aneurysms.

Multiple FDA-approved drugs without lipid-lowering indications were identified to have potential lipid-lowering properties.

Inclisiran was found to have a lower risk of new-onset diabetes compared with other low-density lipoprotein cholesterol (LDL-C)-lowering therapies.

FDA approves inclisiran as a monotherapy to effectively lower low-density lipoprotein cholesterol in adults with hypercholesterolemia, enhancing heart disease prevention strategies.

Kirk Knowlton, MD, discusses findings from the V-INCEPTION trial evaluating inclisiran for low-density lipoprotein cholesterol (LDL-C) management after myocardial infarction, highlighting its real-world effectiveness, tolerability, and potential for integration into pharmacist-led lipid care pathways.

Patients with ASCVD face increased cardiovascular risks post revascularization, yet many miss timely LDL-C testing and treatment, highlighting critical care gaps.

High levels of remnant cholesterol were associated with increased risk of developing metabolic dysfunction-associated steatotic liver disease (MASLD) independent of low-density lipoprotein cholesterol (LDL-C).